Cantargia (OMX: CANTA)

Last close As at 30/06/2025

SEK1.35

0.10 (7.83%)

Market capitalisation

SEK312m

Cantargia is a clinical-stage biotech company based in Sweden. It is developing two assets against IL1RAP, CAN04 and CAN10. CAN04 is being studied in several solid tumours with a main focus on non-small cell lung cancer (NSCLC) and pancreatic cancer. The most advanced trial is in Phase II.

Latest Insights

View More

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash, CFA

Director, healthcare

Key Management

  • Goran Forsberg

    CEO

Flash note

Healthcare

Cantargia — CAN04 progressing on all fronts

Update

Healthcare

Cantargia — Useful insights from CANOPY-1 data

edison tv

Healthcare

Cantargia – executive interview

edison tv

Healthcare

Cantargia: Edison Open House Healthcare 2022

Update

Healthcare

Cantargia — ‘Post-Novartis’ era has begun

edison tv

Healthcare

Cantargia – executive interview

edison tv

Healthcare

Cantargia – executive interview

Flash note

Healthcare

Cantargia — Novartis’s CANOPY-2 trial disappoints

edison tv

Healthcare

Cantargia – Edison Open House interview

Update

Healthcare

Cantargia — Buoyant on CANFOUR and CANOPY interims

edison tv

Healthcare

Executive interview – Cantargia

Update

Healthcare

Cantargia — Excellent end to the year

Update

Healthcare

Cantargia — Full Phase I data presented at ASCO

edison tv

Healthcare

Executive interview – Cantargia

Update

Healthcare

Cantargia — Nidanilimab transitioning to Phase IIa

Update

Healthcare

Cantargia — CANFOUR interim Phase I presented at ESMO

Update

Healthcare

Cantargia — Phase IIa set to start in Q418

Initiation

Healthcare

Cantargia — Tackling tumour promoting inflammation